EA201790400A1 - Зонды для визуализации белка хантингтина - Google Patents

Зонды для визуализации белка хантингтина

Info

Publication number
EA201790400A1
EA201790400A1 EA201790400A EA201790400A EA201790400A1 EA 201790400 A1 EA201790400 A1 EA 201790400A1 EA 201790400 A EA201790400 A EA 201790400A EA 201790400 A EA201790400 A EA 201790400A EA 201790400 A1 EA201790400 A1 EA 201790400A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hantingtin
visualization
probes
protein
compound
Prior art date
Application number
EA201790400A
Other languages
English (en)
Other versions
EA039923B1 (ru
Inventor
Селиа Домингез
Джон Витяк
Джонатан Бард
Алекс Киселев
Кристофер Джон Браун
Майкл Эдвард Прайм
Питер Дэвид Джонсон
Дэниел Кларк-Фрю
Original Assignee
Сиэйчдиай Фаундэйшн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэйчдиай Фаундэйшн, Инк. filed Critical Сиэйчдиай Фаундэйшн, Инк.
Publication of EA201790400A1 publication Critical patent/EA201790400A1/ru
Publication of EA039923B1 publication Critical patent/EA039923B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Настоящее изобретение относится к визуализирующим агентам, содержащим соединение формулы (I) или его фармацевтически приемлемую соль, и способам их применения.
EA201790400A 2014-08-29 2015-08-28 Зонды для визуализации белка хантингтина EA039923B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043590P 2014-08-29 2014-08-29
PCT/US2015/047401 WO2016033440A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (2)

Publication Number Publication Date
EA201790400A1 true EA201790400A1 (ru) 2017-09-29
EA039923B1 EA039923B1 (ru) 2022-03-28

Family

ID=55400645

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790400A EA039923B1 (ru) 2014-08-29 2015-08-28 Зонды для визуализации белка хантингтина

Country Status (20)

Country Link
US (2) US11104691B2 (ru)
EP (1) EP3197277B1 (ru)
JP (1) JP6754353B2 (ru)
KR (1) KR102410733B1 (ru)
CN (1) CN107105667B (ru)
AU (2) AU2015308769A1 (ru)
BR (1) BR112017004140B1 (ru)
CA (1) CA2959533C (ru)
DK (1) DK3197277T3 (ru)
EA (1) EA039923B1 (ru)
ES (1) ES2905095T3 (ru)
HR (1) HRP20220001T1 (ru)
HU (1) HUE057702T2 (ru)
IL (1) IL250802B (ru)
MX (1) MX2017002702A (ru)
PL (1) PL3197277T3 (ru)
PT (1) PT3197277T (ru)
SG (1) SG11201701592SA (ru)
SI (1) SI3197277T1 (ru)
WO (1) WO2016033440A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056957T2 (hu) 2014-08-29 2022-04-28 Chdi Foundation Inc Próbák huntingtin fehérjét megjelenítõ képalkotásra
AU2015308765B2 (en) 2014-08-29 2020-06-04 Chdi Foundation, Inc. Probes for imaging huntingtin protein
MX2017002705A (es) 2014-08-29 2017-12-20 Chdi Foundation Inc Sondas para la proyección de imagen de la proteína huntingtina.
WO2016033440A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
WO2017040336A1 (en) 2015-08-28 2017-03-09 Chdi Foundation, Inc. Probes for imaging huntingtin protein
US20190381030A1 (en) * 2017-10-12 2019-12-19 University Of Kansas Methods of treating radiation induced gastrointestinal syndrome (rigs) and related disease states using yel002/bcn057
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
MX2021013574A (es) 2019-05-09 2021-12-10 Hoffmann La Roche Sintesis de imidazo[1,2-a]pirimidinas etiquetadas.
CN114773312B (zh) * 2021-10-29 2024-03-26 北京鑫诺康桥药物研究有限公司 一种盐酸阿罗洛尔中间体的制备工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
CA2500358A1 (en) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. Probes for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles
EP2042501B1 (en) * 2006-06-21 2017-04-12 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
WO2008016648A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
CN101535309A (zh) * 2006-11-17 2009-09-16 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
NZ577511A (en) * 2006-11-30 2012-04-27 Nihon Mediphysics Co Ltd 2-Phenyl-imidazo[1,2-a]pyridine derivatives substituted with a radioactive halogen substituent
KR20090101469A (ko) * 2007-01-22 2009-09-28 아스트라제네카 아베 신규 헤테로아릴 치환된 이미다조〔１，２­ａ〕피리딘 유도체
KR20100101576A (ko) * 2007-10-30 2010-09-17 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
US8420052B2 (en) * 2008-07-24 2013-04-16 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying AD pathology
WO2010034982A1 (en) * 2008-09-23 2010-04-01 Wista Laboratories Ltd. Ligands for aggregated tau molecules
US8614201B2 (en) * 2009-06-05 2013-12-24 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of TRPA1
AU2012259929B2 (en) * 2011-05-20 2016-08-04 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
CN103596950B (zh) * 2011-06-24 2017-12-19 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的化合物
JP2013237655A (ja) 2012-05-17 2013-11-28 Kyoto Univ コンフォメーション病診断用分子プローブ
CA2884767A1 (en) * 2012-11-14 2014-05-22 Stephan Bachmann Imidazopyridine derivatives
ES2824723T3 (es) 2013-03-14 2021-05-13 Galapagos Nv Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
CN105579453B (zh) * 2013-09-26 2017-12-22 豪夫迈·罗氏有限公司 作为成像工具的咪唑并[1，2‑a]吡啶‑7‑胺类
WO2016033440A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
MX2017002705A (es) 2014-08-29 2017-12-20 Chdi Foundation Inc Sondas para la proyección de imagen de la proteína huntingtina.
HUE056957T2 (hu) 2014-08-29 2022-04-28 Chdi Foundation Inc Próbák huntingtin fehérjét megjelenítõ képalkotásra
AU2015308765B2 (en) 2014-08-29 2020-06-04 Chdi Foundation, Inc. Probes for imaging huntingtin protein
WO2017040336A1 (en) 2015-08-28 2017-03-09 Chdi Foundation, Inc. Probes for imaging huntingtin protein

Also Published As

Publication number Publication date
JP2017529340A (ja) 2017-10-05
KR20170047303A (ko) 2017-05-04
CN107105667A (zh) 2017-08-29
BR112017004140A2 (pt) 2017-12-12
HUE057702T2 (hu) 2022-05-28
CA2959533C (en) 2023-03-07
US11851446B2 (en) 2023-12-26
BR112017004140B1 (pt) 2023-01-10
US11104691B2 (en) 2021-08-31
EA039923B1 (ru) 2022-03-28
MX2017002702A (es) 2017-10-23
AU2019283999B2 (en) 2021-07-22
PT3197277T (pt) 2022-02-01
IL250802A0 (en) 2017-04-30
AU2015308769A1 (en) 2017-03-23
CN107105667B (zh) 2021-08-17
PL3197277T3 (pl) 2022-04-04
EP3197277B1 (en) 2021-12-22
WO2016033440A1 (en) 2016-03-03
KR102410733B1 (ko) 2022-06-20
SG11201701592SA (en) 2017-03-30
CA2959533A1 (en) 2016-03-03
EP3197277A4 (en) 2018-04-18
DK3197277T3 (da) 2022-01-31
US20170283439A1 (en) 2017-10-05
IL250802B (en) 2020-08-31
US20210380608A1 (en) 2021-12-09
JP6754353B2 (ja) 2020-09-09
ES2905095T3 (es) 2022-04-07
EP3197277A1 (en) 2017-08-02
HRP20220001T1 (hr) 2022-04-01
SI3197277T1 (sl) 2022-04-29
AU2019283999A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
EA201792021A1 (ru) Ингибитор jak
EA201892430A1 (ru) Синтез индазолов
EA201790408A1 (ru) Зонды для визуализации белка хантингтина
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
EA201691541A1 (ru) Новые анти-baff антитела
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA201790570A1 (ru) Модуляторы р2х7
MX2018002338A (es) Sondas para formar imagenes de proteina de huntingtina.
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида